Compare · JNJ vs RPRX
JNJ vs RPRX
Side-by-side comparison of Johnson & Johnson (JNJ) and Royalty Pharma plc (RPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and RPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 18.2x RPRX ($33.50B).
- JNJ has been more active in the news (10 items in the past 4 weeks vs 7 for RPRX).
- JNJ has more recent analyst coverage (25 ratings vs 12 for RPRX).
- Company
- Johnson & Johnson
- Royalty Pharma plc
- Price
- -
- -
- Market cap
- $609.12B
- $33.50B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 12
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson
Latest RPRX
- Royalty Pharma declares third quarter 2026 dividend
- Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
- EVP, Research & Investments Urist Marshall sold $508,454 worth of Class A Ordinary Shares (9,099 units at $55.88) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- EVP & Chairman, Partnering Hite Christopher sold $7,345,471 worth of Class A Ordinary Shares (130,000 units at $56.50) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 40,000 units (SEC Form 4)
- Director Bassler Bonnie L was granted 689 units of Class A Ordinary Shares, increasing direct ownership by 0.88% to 79,181 units (SEC Form 4)
- EVP, Research & Investments Urist Marshall sold $502,067 worth of Class A Ordinary Shares (9,098 units at $55.18) as part of a pre-agreed trading plan, decreasing direct ownership by 50% to 9,099 units (SEC Form 4)
- EVP & Chairman, Partnering Hite Christopher sold $8,159,277 worth of Class A Ordinary Shares (150,000 units at $54.40) as part of a pre-agreed trading plan (SEC Form 4)
- Director Weatherman Elizabeth H was granted 4,545 units of Class A Ordinary Shares, increasing direct ownership by 53% to 13,103 units (SEC Form 4)
- Director Norden Gregory was granted 4,545 units of Class A Ordinary Shares, increasing direct ownership by 2% to 196,348 units (SEC Form 4)
- Director Love Ted W was granted 4,545 units of Class A Ordinary Shares, increasing direct ownership by 8% to 58,393 units (SEC Form 4)